| 000 | 01240 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515111041.0 | ||
| 264 | 0 | _c20080226 | |
| 008 | 200802s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMhle0706973 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDudzinski, David M | |
| 245 | 0 | 0 |
_aScientific and legal viability of follow-on protein drugs. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cFeb 2008 |
||
| 300 |
_a843-9 p. _bdigital |
||
| 500 | _aPublication Type: Historical Article; Journal Article | ||
| 650 | 0 | 4 |
_aBiological Products _xstandards |
| 650 | 0 | 4 |
_aDrug Approval _xhistory |
| 650 | 0 | 4 |
_aDrugs, Generic _xhistory |
| 650 | 0 | 4 | _aGovernment Regulation |
| 650 | 0 | 4 | _aHistory, 20th Century |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLegislation, Drug _xhistory |
| 650 | 0 | 4 |
_aPatents as Topic _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aRecombinant Proteins _xstandards |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 700 | 1 | _aKesselheim, Aaron S | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 358 _gno. 8 _gp. 843-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMhle0706973 _zAvailable from publisher's website |
| 999 |
_c17791918 _d17791918 |
||